ABUS · Arbutus Biopharma Corp
United States · RS rating 31 · As of 2026-11-03
| Price | 3.88 USD |
|---|---|
| 1-day change | -3.0% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 24 / 36 / 38 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 21 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -103.5% |
| Sales growth Q/Q | +98.7% |
| Distance from 52-week high | +25.7% |
| Market cap (USD) | $837.0M |